MORE Savings Act

On September 3, 2026, Rep. Madeleine Dean (D-PA) introduced H.R. 10254, the Maximizing Opioid Recovery Emergency Savings Act (MORE Savings Act). The bill was referred to the Committees on Energy and Commerce, Ways and Means, and Education and Workforce. It is in the earliest legislative stage with zero cosponsors and no companion bill in the Senate. The bill mandates that Medicare Parts B, D, and C, as well as private health plans, cover medication-assisted treatment (MAT) for opioid use disorder, opioid overdose reversal medications (e.g., naloxone), and recovery support services (e.g., peer counseling, transportation) without any cost-sharing (copays, coinsurance, deductibles). It also directs CMS to test a model eliminating cost-sharing for these services in 15 states. The bill does not authorize any specific appropriation; it imposes coverage mandates that shift costs from patients to insurers and the federal government. The primary beneficiaries are manufacturers of MAT drugs (buprenorphine products) and naloxone products, as removal of cost-sharing increases utilization and reduces price sensitivity. Key companies include Indivior ($INDV, Suboxone film), Opiant Pharmaceuticals (, Narcan royalties), and Viatris (, generic naloxone). However, the bill is early-stage, with a low probability of passage in its current form. No convergence signals were identified. The legislative path requires committee markups, House passage, Senate introduction and passage, and presidential action. Given the partisan environment and the bill's cost to insurers and Medicare, significant hurdles remain. Investors should monitor committee activity and cosponsor additions as indicators of momentum.